Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 21, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who serves as CEO, President, Chairman, Director, and 10% Owner of IRADIMED Corp, reported sales of common stock.
• The transactions occurred on October 21, 2025.
• A total of 5,000 shares of common stock were sold in two separate transactions.
• The first sale involved 3,577 shares at a weighted average price of $74.58 per share.
• The second sale involved 1,423 shares at a weighted average price of $75.41 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• Following these transactions, Roger E. Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust is 2,332,500 shares.
• Additional indirect beneficial ownership includes 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust.

Sentiment

Score: 5

Explanation: The sale of shares by a key executive, even under a Rule 10b5-1 plan, can be viewed with slight caution by investors. However, the pre-planned nature significantly reduces the immediate negative sentiment often associated with insider selling, leading to a neutral to slightly cautious sentiment.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, though this is mitigated by the Rule 10b5-1 plan.

Future Outlook

The existence of a Rule 10b5-1 plan indicates a pre-determined future selling strategy for the reporting person, suggesting planned diversification or liquidity management.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This filing details an individual insider trading activity and does not provide broader industry context or trends.

Related Party Transactions

• The reported sales involved shares indirectly owned through various family trusts (Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, Matthew Susi 2008 Dynasty Trust), which are considered related parties to the reporting person.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the pre-arranged Rule 10b5-1 plan mitigates immediate concerns about the company's short-term prospects.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, these sales were conducted under a pre-arranged Rule 10b5-1 plan, which suggests a planned diversification or liquidity event rather than a reaction to new negative information. Without additional context on the company's performance or other market factors, a neutral 'hold' recommendation is appropriate, acknowledging the planned nature of the transaction.

Keywords

IRADIMED Corp, IRMD, Roger E. Susi, Insider Sale, Form 4, 10b5-1 Plan, Common Stock, CEO, Director, 10% Owner